Intec Pharma (XTAE:NTEC) Momentum Rank : 0 (As of Jun. 16, 2024)

View and export this data going back to 2010. Start your Free Trial

What is Intec Pharma Momentum Rank?

Intec Pharma has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Intec Pharma Momentum Rank Related Terms

Thank you for viewing the detailed overview of Intec Pharma's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Intec Pharma (XTAE:NTEC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intec Pharma Ltd (XTAE:NTEC) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

12 Hartom Street, Har Hotzvim, Jerusalem, ISR, 9777512

Website

https://www.intecpharma.com

Intec Parent Inc, formerly Intec Pharma Ltd is a clinical-stage biopharmaceutical company based in Israel. The company is focused on research and development and clinical trials. The company develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing efficient gastric retention. Accordion Pill Carbidopa/Levodopa or AP-CDLD is being developed by the company for the indication of treatment of Parkinson's disease.